Arena Pharma (ARNA) Tops Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. LEVI
3. SBUX
4. NVDA
5. GOOGL
6. AAPL
7. SPY
8. APLD
9. ORCL
10. USO

Go back to Arena Pharma (ARNA) Tops Q2 EPS by 3c

Arena Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update

August 5, 2015 4:01 PM EDT

SAN DIEGO, Aug. 5, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the second quarter ended June 30, 2015, and provided a corporate update.

"We have continued to advance our deep clinical-stage pipeline, as evidenced by the recent initiation of a Phase 2 proof-of-concept clinical trial of APD334, our internally discovered S1P1 receptor modulator, in ulcerative colitis," stated Jack Lief, Arena's President and Chief Executive Officer. "We are also supporting our collaborators' efforts to increase patient access and use of BELVIQ, including by working to obtain regulatory... More